全文获取类型
收费全文 | 1539篇 |
免费 | 83篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 35篇 |
妇产科学 | 12篇 |
基础医学 | 209篇 |
口腔科学 | 21篇 |
临床医学 | 93篇 |
内科学 | 249篇 |
皮肤病学 | 44篇 |
神经病学 | 165篇 |
特种医学 | 27篇 |
外国民族医学 | 1篇 |
外科学 | 397篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 102篇 |
眼科学 | 32篇 |
药学 | 62篇 |
中国医学 | 1篇 |
肿瘤学 | 134篇 |
出版年
2023年 | 13篇 |
2022年 | 16篇 |
2021年 | 48篇 |
2020年 | 20篇 |
2019年 | 34篇 |
2018年 | 31篇 |
2017年 | 32篇 |
2016年 | 41篇 |
2015年 | 35篇 |
2014年 | 48篇 |
2013年 | 62篇 |
2012年 | 101篇 |
2011年 | 127篇 |
2010年 | 75篇 |
2009年 | 58篇 |
2008年 | 90篇 |
2007年 | 87篇 |
2006年 | 69篇 |
2005年 | 69篇 |
2004年 | 83篇 |
2003年 | 57篇 |
2002年 | 54篇 |
2001年 | 60篇 |
2000年 | 41篇 |
1999年 | 44篇 |
1998年 | 20篇 |
1997年 | 10篇 |
1996年 | 19篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 11篇 |
1992年 | 16篇 |
1991年 | 12篇 |
1990年 | 16篇 |
1989年 | 11篇 |
1988年 | 10篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 7篇 |
1982年 | 6篇 |
1979年 | 7篇 |
1978年 | 3篇 |
1975年 | 4篇 |
1974年 | 8篇 |
1971年 | 4篇 |
1970年 | 3篇 |
1959年 | 3篇 |
1869年 | 4篇 |
排序方式: 共有1624条查询结果,搜索用时 78 毫秒
991.
992.
993.
994.
Calvo-Alén J McGwin G Toloza S Fernández M Roseman JM Bastian HM Cepeda EJ González EB Baethge BA Fessler BJ Vilá LM Reveille JD Alarcón GS;LUMINA Study Group 《Annals of the rheumatic diseases》2006,65(6):785-790
BACKGROUND: Osteonecrosis is common in systemic lupus erythematosus (SLE) and often disabling. The role of glucocorticoids in its development is well known. OBJECTIVE: To explore other possible risk factors for osteonecrosis in SLE. METHODS: A nested matched case-control study undertaken in the context of a large, longitudinal, multiethnic lupus cohort (LUMINA), currently formed of 571 SLE patients meeting American College of Rheumatology criteria. All those developing symptomatic osteonecrosis after the diagnosis of SLE were considered cases. Two controls matched for age, disease duration, ethnicity, and centre were selected for each case. Cases and controls were compared by univariable analyses using selected variables. Variables with p<0.10 and those thought clinically relevant were entered into conditional logistic regression models including either the average dose or the highest dose of glucocorticoids, with osteonecrosis as the dependent variable. RESULTS: 32 cases were identified and 59 matched controls selected (in five cases only one control could be found). By univariable analyses, both groups were largely comparable for socioeconomic-demographic, clinical, and laboratory variables. Cases were less exposed to hydroxychloroquine (as assessed by the percentage of exposure time) (p = 0.026), used higher doses of glucocorticoids (average and highest doses) (p = 0.011 and 0.001, respectively), and received cytotoxic drugs more often (p = 0.015). In the multivariable analyses only cytotoxic drug use (both models) and the highest dose of glucocorticoids remained associated with the occurrence of osteonecrosis. CONCLUSIONS: Cytotoxic drug use is a risk factor for the development of symptomatic osteonecrosis in SLE patients, along with glucocorticoids. No definite protective factors were identified. 相似文献
995.
Vilá LM Alarcón GS McGwin G Bastian HM Fessler BJ Reveille JD;Lumina Study Group 《Arthritis and rheumatism》2006,55(5):799-806
OBJECTIVE: To determine if lymphopenia is associated with clinical/immunologic manifestations, disease activity, and disease damage in systemic lupus erythematosus (SLE). METHODS: The study group comprised 591 patients with SLE participating in a multiethnic, longitudinal outcome study. Cumulative clinical/immunologic (per American College of Rheumatology criteria) and pharmacologic treatment variables were obtained at enrollment (T0) and last visit (TL). Lymphopenia (<1,500/mm3) was scored only when clinically attributable to SLE and not to medications or other causes. Lymphocyte counts were expressed in 4 categories per the Systemic Lupus Activity Measure (SLAM): normal (> or =1,500/mm3), mild (1,000-1,499/mm3), moderate (500-999/mm3), and marked (<500/mm3). Disease activity was assessed with the SLAM and the Physician's Global Assessment (PGA). Disease damage was determined with the Systemic Lupus International Collaborating Clinics Damage Index (SLICC-DI). The relationship of lymphopenia with cumulative clinical/immunologic and pharmacologic treatment variables was first examined, then the association between the SLAM, PGA, and SLICC-DI scores with different categories of lymphopenia was examined by generalized estimating equation (GEE) regression analyses. Ethnicity, age, and sex were entered into all regression models. RESULTS: At T0 and TL, lymphopenia was found to be positively associated with renal involvement, leukopenia, anti-double-stranded DNA antibodies, anti-Ro antibodies, and the use of glucocorticoids, azathioprine, and methotrexate, but was negatively associated with photosensitivity. On GEE analyses, marked lymphopenia at T0 and moderate and marked lymphopenia for all visits were independently associated with higher SLAM, PGA, and SLICC-DI scores. CONCLUSION: Lymphopenia is associated with several clinical/immunologic manifestations in SLE. Moderate and marked lymphopenia are associated with higher disease activity and damage accrual. 相似文献
996.
Diagnosing Kawasaki syndrome 总被引:1,自引:0,他引:1
997.
Primary immunodeficiency disorders (PIDs) continue to illuminate mechanisms of human immunity and hypersensitivity. New discoveries
in common variable immunodeficiency, the most enigmatic of PID syndromes, reveal molecular pathways of importance in human
antibody production. FOXP3 mutations demonstrate the essential role that T-regulatory cells play in controlling autoantibody formation and disease.
Interleukin-1 receptor-associated kinase 4 deficiency emphasizes the key role that innate immunity plays in the defense of
bacterial disease occurring early in life. With respect to therapy, subcutaneous immunoglobulin treatment may indeed be a
better treatment than intravenous immunoglobulin for many patients with antibody deficiency. Finally, PIDs remain in the vanguard
for the treatment of inherited disorders by gene therapy. Gene therapy has cured patients with chronic granulomatous disease
and severe combined immunode ficiency, but not without morbidity and mortality. Into the 21st century, PIDs continue to instruct
us in human health and disease. 相似文献
998.
999.
1000.
Bertoli AM Vilá LM Apte M Fessler BJ Bastian HM Reveille JD Alarcón GS;LUMINA Study Group 《Rheumatology (Oxford, England)》2007,46(9):1471-1476
OBJECTIVE: To examine if anaemia (and its severity) is associated with disease activity and damage accrual in systemic lupus erythematosus (SLE). METHODS: Four thousand four-hundred study visits in 613 SLE patients enrolled in LUMINA were studied. Anaemia was expressed in four categories of haematocrit (Hct) as defined by the Systemic Lupus Activity Measure-Revised (SLAM-R): no anaemia (Hct >35%), mild (Hct = 30-35%), moderate (Hct = 25-29%) and severe (Hct <25%). Anti-dsDNA antibodies were measured at baseline. Disease activity was assessed with the SLAM-R and damage with the Systemic Lupus International Collaborating Clinics Damage Index (SDI). The relationship between anaemia and anti-dsDNA antibodies with the SLAM and SDI scores was examined by univariate (one-way ANOVA) and multivariate (generalized linear models and generalized estimating equation regression) analyses. RESULTS: All categories of anaemia and anti-ds DNA were significantly associated with the SLAM-R at baseline and over time. However, only moderate and severe anaemia were associated with the SDI at baseline and over time, while the presence of anti-ds DNA was only associated with the SDI over time but not at baseline. Several clinical domains of the SLAM-R and SDI were associated with anaemia at baseline and over time. CONCLUSIONS: Mild, moderate and marked anaemia are strongly associated with disease activity in SLE. Moderate and marked anaemia are associated with damage accrual. These associations are observed both early and during the course of SLE. Different levels of anaemia could be used to monitor disease activity and predict organ/system damage in SLE. 相似文献